Nonmotor fluctuations in Parkinson disease
Severity and correlation with motor complications
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 3, 2012
- Accepted October 24, 2012
- First Published January 30, 2013.
Article Versions
- Previous version (January 30, 2013 - 13:03).
- You are viewing the most recent version of this article.
Author Disclosures
- Alexander Storch, MD,
- Christine B. Schneider, MD,
- Martin Wolz, MD,
- Yannic Stürwald,
- Angelika Nebe, MD,
- Per Odin, MD, PhD,
- Andreas Mahler, MD,
- Gerd Fuchs, MD,
- Wolfgang H. Jost, MD,
- K. Ray Chaudhuri, DSc, MD,
- Rainer Koch, MD, PhD,
- Heinz Reichmann, MD, PhD and
- Georg Ebersbach, MD
- Alexander Storch, MD,
Member of advisory boards: Boehringer Ingelheim; Ingelheim, Germany (since 2006), Cephalon, Munich, Germany, (since 2006), Valeant Pharma, Frankfurt, Germany (since 2007), UCB Schwarz Pharma, Monheim, Germany (since 2007), Lundbeck Phrma, Hamburg, Germany, and Teva Pharma, Mörfelden-Walldorf, Germany (since 2009), Merz Pharma, Frankfurt, Germany (since 2011), Archimedes Pharma, Munich, Germany (since 2012).
NONE
Travel money for visiting a meeting from Boehringer, Ingelheim, Germany (2009), and Teva Pharma, Mörfelden, Germany (2012).
Editorial board member of Stem Cells, Stem Cells, International, The Open Biotechnology Journal, The European Neurological Journal
NONE
NONE
1) Employment at the German Centre for Neurodegenerative, Diseases (DZNE), Dresden (non-profit, goverment institution), 2) Honoraria for presentations from Cephalon, Lundbeck, Boehringer Ingelheim, Teva, UCB, Meda, Abbott, GlaxoSmithKline, GE HealthCare, Novartis, NeuroConsil, Carus Management, Gruenenthal, Orion, Bayer HealthCare, Medtronic, SWEMODIS. Payment for manuscript preparation from Archimedes, Munich, Germany.
NONE
NONE
NONE
NONE
I have received unrestricted research grants from Boehringer Ingelheim, Germany, Pfizer Pharma, Germany, Teva Pharma Germany, and UCB Pharma, Germany.
I have received grant money from the Bundesministerium für Bildung und Forschung, Germany, Federal Ministry of Economy, Germany, the Helmholtz Association, and the Deutsche Forschungsgemeinschaft (DFG).
NONE
I have received grant money from the Thyssen Foundation, Germany, the Roland-Ernst Foundation, Germany, the International Parkinson Foundation, Germany, the NA, Advocacy, UK, and the NCL foundation, Gemany.
NONE
NONE
NONE
NONE
NONE
NONE
- Christine B. Schneider, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Martin Wolz, MD,
NONE
NONE
honoraria for presentations from Boehringer Ingelheim, GlaxoSmithKline, Valeant, MEDA Pharma, Medtronic, TEVA and UCB Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yannic Stürwald,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Angelika Nebe, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Per Odin, MD, PhD,
Abbott, Stada
NONE
Abbott, UCB, Stada
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Abbott
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andreas Mahler, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gerd Fuchs, MD,
1 UCB, 2 Boehringer, 3 Orion
NONE
1 UCB, 2 Boehringer
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Wolfgang H. Jost, MD,
Scientific advisory board: Allergan, Boehringer Ingelheim,Desitin, GlaxoSmithKline, Merz
NONE
NONE
Editor-in-chief: Basal Ganglia
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- K. Ray Chaudhuri, DSc, MD,
Scientific advisory board for Abbott, Boehringer-Ingelheim, GSK, Serrono, Teva, UCB, Britannia pharmaceuticals between 2007-2012 and received honorarium for scientific advise.
NONE
NONE
Parkinson's disease and related disorder. Editorial board since 2009, European Editor Basal ganglia, Editorial board: Journal of Parkinson's Disease
NONE
NONE
Honoraria for advisor in scientific advisory boards as listed above. Honoraria for lectures in international scientific meetings (EFNS, Swedish Movement Disorders Society, LIMPE Italy 2007-2009, MDS (Paris)) MDS 2010,2011, EFNS 2011, WPD 2010, WFN PRD 2011
1: PDNMG, 2: Mundipharma
NONE
NONE
NONE
Research support for a clinical research nurse from UCB Pharma (2008-2009). Solvay (clinical fellow) Educational grant from UCB, Abbott, Boehringer for EUROPAR - an European Multicentre PD non motor studies programme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rainer Koch, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Heinz Reichmann, MD, PhD and
Abbott, Cephalon, Novartis, TEVA, Lundbeck, GSK, Boehringer Ingelheim, Schering/Bayer Health Care, UCB/Schwarz Pharma, Desitin, Merck-Serono, Solvay
NONE
for advisory board meetings or lectures. Cephalon, Novartis, TEVA, Lundbeck, GSK, Boehringer Ingelheim, Schering/Bayer Health Care, Pfizer, UCB/Schwarz Pharma, Desitin,Solvay.
UCB/Schwarz Pharma, GSK
NONE
NONE
Cephalon, Novartis, TEVA, Lundbeck, GSK, Boehringer Ingelheim, Schering/Bayer Health Care, Pfizer, UCB/Schwarz Pharma, Desitin,Solvay (2008/2009)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Georg Ebersbach, MD
Desitin Pharma, Novartis Pharma, Boehringer Pharma, Archimedes Pharma, Orion Pharma, Britannia Pharma
NONE
Desitin Pharma, MEDA Pharma, Glaxo SmithKline Pharma, Boehringer Pharma, Novartis Pharma, Archimedes Pharma, Orion Pharma, TEVA Pharma, UCB Pharma, Abbot Pharma
NONE
NONE
NONE
NONE
Novartis Pharma, Archimedes Pharma, Licher GmbH, Britannia Pharma
NONE
NONE
NONE
NONE
NONE
NONE
Deutsche Parkinson Vereinigung (patient organisation)
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology, Division of Neurodegenerative Diseases (A.S., C.B.S., M.W., Y.S.), Department of Medical Informatics and Biometry (R.K.), and Department of Neurology (H.R.), Dresden University of Technology, Dresden; German Center for Neurodegenerative Diseases (DZNE) (A.S.), Dresden; Movement Disorders Clinic (A.N., G.E.), Beelitz-Heilstätten; Department of Neurology (P.O., A.M.), Klinikum Bremerhaven, Bremerhaven, Germany; Department of Neurology (P.O), University Hospital, Lund, Sweden; Parkinson Clinic Wolfach (G.F.), Wolfach; Department of Neurology (W.H.J.), Deutsche Klinik für Diagnostik, Wiesbaden, Germany; and National Parkinson Foundation Centre of Excellence (K.R.C.), Kings College Hospital and Kings College London and Biomedical Research Centre, Kings College London, London, UK.
- Correspondence to Dr. Storch: alexander.storch{at}neuro.med.tu-dresden.de
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.